EGFR and non-small cell lung carcinoma: The kinase domain of the epidermal growth factor receptor (EGFR) is an established drug target in non-small cell lung cancer (NSCLC) where oncogenic mutations often predict clinical responsiveness to treatment with certain TKIs37.